Organization
Azienda Ospedaliera di Rilievo Nazionale Specialistica dei Colli Monaldi
1 abstract
Abstract
Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).Org: Netherlands Cancer Institute, Henry Dunant Hospital, Universitätsspital Zürich, University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre,